Our Platform
Three Pillars.
One Self-Sustaining Model.
Three complementary pillars — each reinforcing the others, together forming a platform where science and commerce advance in step.
Pillar 1 · The Long-Term Value Engine
Regenerative Science & EV Biotech
The intellectual and scientific core of BICC — where the science is developed, the IP is built, and the long-term value of the platform compounds.
A*STAR Collaboration
RCA signed. Joint MSC-derived EV development with IP co-ownership — BICC's share grows with its input.
Manufacturing Platform
cGMP-compliant by design. Bioreactor scale-up in progress. 3–5L per batch, 9–14 day cycle.
Distribution Pipeline
EV cosmeceutical products — H2 2026 first shipments. LOIs from three distributors, 300+ clinic touchpoints.
Wound Care
CE Mark application underway. Two hospital pilots in discussion. A medium-term revenue stream.
Therapeutic Pipeline
Diabetes, fatty liver disease and neurodegeneration — the long-term pipeline that expands the platform's reach and value.
Pillar 2 · Revenue & Growth Today
Health & Profiling Services
Where BICC earns today and scales fast — built around the Longevity Stack™. Recurring relationships, not one-off sales.
The Longevity Stack™
1
Test
Risk Profiling
Gut microbiome analysis and DNA profiling — 300+ health markers
2
Diagnose
Health Report
Metabolic health, gut flora and inflammation markers — detailed & personalised
3
Recommend
Protocol
Personalised, evidence-based protocol tailored to the individual
4
Supplement
BICC Products
Probiotics, NMN and a growing range of health products
↺ Repeat and upsell — the journey drives recurring revenue.
Connection Care℠
BICC's teleconsultation platform — the digital connective tissue that allows the entire model to scale beyond any single physical location.
Coordinates the Stack
Partners deliver gut profiling, DNA profiling, probiotics and EV products through one BICC-managed pathway.
Data-Sovereign
Hosted in Singapore. Partner doctors retain patient records; BICC manages the referral and product layer.
Three Revenue Streams
Consultation fees, referral fees, and product sales triggered through the platform.
Timeline
First live node Q3 2026 · South-East Asia rollout 2027
Cross-Border Clinical Coordination
A profiling-led patient journey across an accredited regional clinic network — coordinated through Connection Care℠ and delivered under the appropriate regulatory framework in each market.
The Journey
Digital consultation → health profiling workup → coordinated referral → post-care follow-up and supplement recommendations.
Accredited Partner Network
MOU in place with an established accredited medical centre in the region.
Revenue
Coordination and referral fees, pre- and post-care product sales, revenue-sharing as the network matures.
Pillar 3 · Stable, Defensive Cash Flow
Healthcare Support & Distribution
Established operating companies generating recurring revenue today — providing the healthcare infrastructure backbone that makes the whole platform self-sustaining.
Healthcare Infrastructure & Support
Healthcare Infrastructure & Engineering
Established businesses providing hospital, healthcare building and laboratory fit-outs, as well as smart wellness and hospital technology — IoT systems for clinical and wellness environments.
Cold-Chain & Logistics Infrastructure
Specialised cleanroom and cold-chain infrastructure — a critical capability for the storage, handling and distribution of health products and biologics across the BICC network.
Distribution Channel Development
Actively building distribution channels for BICC's health and longevity product lines across Singapore and the broader South-East Asia region — through partner clinics, wellness centres and specialist distributors.
Health Products Distribution
An active, revenue-generating business distributing a curated suite of health and longevity products — B2B first, through partner clinics, wellness centres and distributors.
NMN Supplement
Hydrogen Water
Spring Water
— Coming Soon —
Enhanced Probiotics
— Coming Soon —
Further Ranges
Platform Progress
Where We Are Today.
A clear-eyed view of what is live and active across all three pillars — what is generating revenue, what is signed and underway, and what is in active development.
● Live — Generating Revenue
DNA & Gut Profiling
Live since November 2025 · 300+ health markers · Partner network active
Health Supplements
NMN, hydrogen water & spring water · Live since Feb–Mar 2026 · 5,000+ units across SG & Thailand
Gut Profiling Analysis
Accredited clinical research partner signed · Initial cases underway · Full rollout August 2026
A*STAR Research Collaboration
RCA signed · EV research & IP co-ownership active · Joint development underway
◆ Committed — Signed & Agreed
EV Skincare & Anti-Ageing
H2 2026 first shipments — SG, China & Thailand · Three distribution channels — 300+ clinic touchpoints
EV Wound Care
Two clinic pilots in active discussion · International certification in progress
Cross-Border Clinical Coordination
MOU signed with accredited regional medical centre · Connection Care℠ integration in progress
▶ In Progress — Active Development
Connection Care℠ Platform
Technology build underway · First live node Q3 2026 · SEA rollout 2027
EV Wound Care
August 2026 target · Packaging, branding & logistics being finalised
Cross-Border Clinical Coordination
3–5 Singapore clinics targeted 2026 · Active discussions in Thailand · Capital-light partnership model
Why BICC
Science That Pays for Itself.
Built to Scale.
Most regenerative medicine companies are entirely dependent on external funding to sustain their research. BICC is structured differently — our health services and infrastructure businesses generate operating revenue today, funding the EV science platform without diluting the mission or the timeline.
The result is a platform that can move at the pace of science, not the pace of fundraising — advancing Extracellular Vesicle technology from cosmeceuticals to clinical applications, anchored by a signed Research Collaboration Agreement with A*STAR, Singapore's national research agency.